Previous Close | 0.5275 |
Open | 0.5240 |
Bid | 0.5957 x 200 |
Ask | 0.7967 x 100 |
Day's Range | 0.5185 - 0.6500 |
52 Week Range | 0.3700 - 49.8000 |
Volume | |
Avg. Volume | 438,034 |
Market Cap | 8.746M |
Beta (5Y Monthly) | 1.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.7300 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 120.00 |
Seelos Therapeutics' experimental ALS drug did not meet the main goal of a mid-stage trial, the company said on Tuesday, the latest study setback in a field littered with clinical failures. The drug, SLS-005, when tested in 120 patients, failed to show statistically significant improvement in motor function and reducing mortality in patients with ALS, or amyotrophic lateral sclerosis, versus a placebo. ALS affects 16,000 to 32,000 people in the United States, and has long eluded researchers searching for an effective treatment.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in caring for the ALS community. Their unique and innovative approach continues
Seelos Therapeutics, Inc. (Nasdaq: SEEL) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ("CNS") and rare diseases, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 3,404,256 shares of its common stock in a registered direct offering and unregistered common warrants exercisable for up to an aggregate of 3,404,256 shares of common